NCT05008016

Procalcitonin Level and the High Risk of Mortality in 30 Days in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Patient , Cases Series.

Procalcitonin Level and the High Risk of Mortality in 30 Days , in Critically Ill Patients Infected by SARS-CoV-2, Experience of a North African Hospital University , Cases Series.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 582 (actual)
• Sponsor: Mohammed VI University Hospital · Academic / Other
• Sex: All
• Age: 15 Years
• Healthy volunteers: —

Summary

Background: Procalcitonin (PCT) is a biomarker that has been proposed as a helpful tool in inflammatory Clinique cases specially patient with pulmonary bacterienne infection . Materials and methods the investigatore had retrospectively reviewed the electronic records and lists of all 582 COVID-19 patients admitted on the ICU of Hospital university Mohammed VI , Oujda. Between 01 juin 2020 and 31juanary 2021 , and analyzed the relation of PCT value and mortality at 30 days until we can defined a cut off Procalcitonine to use as a marker of severity and high mortality .

Detailed description

Our objective is to assess the relationship between Procalcitonin and 30-day mortality in patients admitted to the resuscitation department of the Mohammed VI University Hospital Center, Oujda, Morocco, infected by the SARS COV 2 Virus .

Conditions

• the Relationship Between Procalcitonin and 30-day Mortality in COVID Patients

Timeline

• Start date: 2020-01-01
• Primary completion: 2020-01-01
• Completion: 2021-01-31
• First posted: 2021-08-17
• Last updated: 2021-08-17

Locations

1 site across 1 country: Morocco